At the 2019 annual meeting of the American Society of Clinical Oncology, investigators and clinicians from St. Jude Children’s Research Hospital present data on how chronic health conditions affect childhood cancer survivors. Novel therapies for solid tumors and the newly expanded resources in St. Jude Cloud are among the topics St. Jude experts will discuss at the five-day meeting that begins Friday, May 31, in Chicago.
St. Jude CEO Presents Award Lecture
The Molecular Pathology of Pediatric Cancer
Sunday, June 2: 11:30 a.m.–12:15 p.m.
Location: S504
St. Jude President and CEO James R. Downing, MD, gives the 2019 Pediatric Oncology Award and Lecture on the molecular pathology of pediatric cancer. Downing was awarded the honor for his scientific achievements and leadership in the field of pediatric oncology.
St. Jude Cloud
St. Jude Cloud is a data-sharing resource for the global research community. More than 600 clinical genomic cases are now available in St. Jude Cloud. Researchers can explore unique next-generation sequencing data and analysis tools, including the newly launched GenomePaint, for pediatric cancer and other life-threatening diseases.
Learn more at Booth #3064
Select Oral Abstracts
When: Friday, May 31 from 3:57 – 4:09 p.m. CST
Where: S504
Title: Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.
Oral Abstract session: Pediatric Oncology I
Abstract 10004
Jeffrey Rubnitz, MD, PhD, of the Department of Oncology will discuss safety and activity of venetoclax in combination with high-dos cytarabine in children with relapsed or refractory acute myeloid leukemia.
When: Sunday, June 2 from 8:00 — 8:12 a.m.
Where: S504
Title: Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Oral Abstract session: Pediatric Oncology II
Abstract 10009
Giles Robinson, MD, of the Department of Oncology will discuss a Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system tumors.
When: Sunday, June 2 from 10:12 – 10:24 a.m.
Where: S504
Title: Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) in the Childhood Cancer Survivor Study.
Oral Abstract session: Pediatric Oncology II
Abstract 10016
Stephanie Dixon, MD, of the Department of Oncology will discuss chronic health conditions and late mortality in survivors of acute lympoblastic leukemia in the Childhood Cancer Survivor Study.
-
Date: Saturday, June 1
Time: 1:45 – 1:57 p.m.
Location: S504
Poster Discussion Session: Pediatric OncologyAlberto Pappo, MD, director of the Developmental Biology and Solid Tumor Program at St. Jude will discuss investigating pediatric solid tumors: from single institution to international collaboration. This poster session discussion will include information from the Malignant Germ Cell Tumor International Consortium (MaGIC) as well as preliminary results around emerging treatment options.
Date: Monday, June 3
Time: 4:30 – 4:42 p.m.
Location: S102
Poster Discussion Session: Symptoms and SurvivorshipTara Brinkman, PhD, will discuss “Attention Gen AYA.” This poster session discussion will include information about how physical and mental health can affect young adult cancer patients and survivors.
-
Pediatric Oncology Posters
When: Saturday, June 1 at 8:00 – 11:00 a.m.
Location: Hall AAbstract Author 10019: Real-time sharing of comprehensive clinical genomics sequencing data in St. Jude Cloud.
Poster #401Scott Newman, PhD 10026: Frailty among childhood cancer survivors: a report from the Childhood Cancer Survivor Study.
Poster #408Samah Hayek, DrPh 10027: Impact of protein supplementation on lean muscle mass in adult survivors of childhood cancer engaged in resistance training.
Poster #409Matthew Krull 10048: Renal function after treatment for childhood cancer: A report from the St. Jude Lifetime Cohort Study
Poster #430Daniel Green, MD 10049: Patient reported outcomes (PROs) in adult survivors of childhood hematopoietic cell transplant (HCT): A report from the St. Jude lifetime cohort study
Poster #431Neel Bhatt, MBBS, MPH 10052: Cost-effectiveness of screening guidelines to present heart failure in childhood cancer survivors: A report from the Childhood Cancer Survivor Study.
Poster #434Matthew Ehrhardt, MD 10057: Progression of frailty in young adult survivors of childhood cancer: St. Jude Lifetime Cohort
Poster #439Kirsten Ness, PhD 10058: Cardiac events in survivors of childhood cancer treated in more recent eras: A report from the Childhood Cancer Survivor Study
Poster #440Daniel Mulrooney, MD, MS 10060: Polygenic risk of subsequent thyroid cancer after childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and childhood cancer survivor study (CCSS)
Poster #442Zhaoming Wang, PhD Cancer Prevention, Hereditary Genetics, and Epidemiology Posters
When: Monday, June 3 at 1:15 – 4:15 p.m.
Location: Hall AAbstract Author 1516: Genome-wide association study using whole-genome sequencing to identify a novel locus associated with cardiomyopathy risk in adult survivors of childhood cancer: Utility of a two-stage analytic approach.
Poster #10Yadav Sapkota, PhD
St. Jude Pioneer Recognized in 2019 Giants of Cancer Care
First St. Jude CEO and Director Donald Pinkel, MD, revolutionized pediatric acute lymphoblastic leukemia treatment. This year, he is honored by OncLive as a 2019 inductee to the Giants of Cancer Care for his work in pediatric oncology.
Read the Research Highlight
Learn More About Dr. Pinkel's Career at St. Jude